3 reports

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Ambulatory Care
  • Antifungal
  • Digestive System Disorder
  • United States
  • Product Initiative

IT WAS ALSO UNDER DEVELOPMENT FORAUTOIMMUNE DISEASES AND ALLERGIES.

  • Ambulatory Care
  • Dermatology
  • United States
  • World
  • Product Initiative

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Ambulatory Care
  • Antifungal
  • Digestive System Disorder
  • Therapy
  • United States